Fibromyalgia is one of the numerous comorbidities that may accompany inflammatory rheumatic diseases. Concomitant fibromyalgia in inflammatory rheumatic conditions can interfere with symptomatology, disease activity and overall management plan. The aim of the present narrative review article was to discuss the current evidence on (i) the prevalence/frequency of comorbid fibromyalgia in inflammatory rheumatic conditions, (ii) the role of fibromyalgia on disease activity, (iii) the impact of concomitant fibromyalgia on biological disease-modifying antirheumatic treatment outcomes and (iv) potential effectiveness of biological disease-modifying antirheumatic drugs on fibromyalgia-related symptoms among patients with inflammatory rheumatic diseases. A literature search was conducted through PubMed/MEDLINE Cochrane and Web of Science databases by using relevant keywords and their combinations. Studies representing different geographical areas of the world revealed that frequency rates of fibromyalgia are higher in inflammatory rheumatic diseases than those in the general population. Comorbid fibromyalgia interferes not only with the disease activity scores but also with the treatment outcomes and management plan. Further evidence is warranted in order to determine the potential benefits of biological disease-modifying antirheumatic drugs on fibromyalgia-related symptoms in patients with inflammatory rheumatic diseases.

中文翻译：

---

纤维肌痛会干扰炎症性风湿性疾病的疾病活动性和生物治疗反应。

纤维肌痛是炎症性风湿病可能伴随的众多合并症之一。炎症性风湿性疾病中伴随的纤维肌痛可能会干扰症状、疾病活动性和整体治疗计划。本叙述性综述文章的目的是讨论以下方面的当前证据：(i) 炎症性风湿病中合并纤维肌痛的患病率/频率，(ii) 纤维肌痛对疾病活动的作用，(iii) 伴随纤维肌痛对疾病活动的影响生物疾病缓解抗风湿治疗结果以及（iv）生物疾病缓解抗风湿药物对炎症性风湿性疾病患者纤维肌痛相关症状的潜在疗效。使用相关关键词及其组合，通过 PubMed/MEDLINE Cochrane 和 Web of Science 数据库进行文献检索。代表世界不同地理区域的研究表明，炎症性风湿性疾病中纤维肌痛的发生率高于普通人群。共病纤维肌痛不仅会影响疾病活动评分，还会影响治疗结果和管理计划。为了确定生物疾病缓解抗风湿药物对炎症性风湿病患者纤维肌痛相关症状的潜在益处，需要进一步的证据。